Pharmaceutical Benefits Scheme cost sharing, patient cost consciousness and prescription affordability

Australian Health Review

Volumn 35, Issue 1, 2011, Pages 37-44

  Doran, Evan ^a   Robertson, Jane ^a   Salkeld, Glenn ^b  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79952161290     PISSN: 01565788     EISSN: 14498944     Source Type: Journal    
DOI: 10.1071/AH10902     Document Type: Article

References (25)

1. Sansom L. The subsidy of pharmaceuticals in Australia: processes and challenges. Aust Health Rev 2004; 28(2): 194-205. doi:10.1071/ AH040194
2. Sweeny K. Key aspects of the Australian Pharmaceutical Benefits Scheme, Working Paper No. 35, Melbourne: Centre for Strategic Economic Studies, Victoria University of Technology; 2007. Available at http://www.cfses.com/documents/ pharma/35-Key-aspects-of-PBS-Sweeny. pdf [verified 2 February 2011].
3. Sweeny K. The impact of co-payments and safety nets on PBS expenditure. Aust Health Rev 2009; 33(2): 215-30. doi:10.1071/ AH090215
4. Graham G. The Australian Pharmaceutical Benefits Scheme. Aust Prescr 1995; 18: 42-4. Available at http://www.australianprescriber.com/magazine/ 18/2/42/4/ [verified 8 December 2009].
5. Martens JM.Whois winning?The drug companies, the government or the battlers? Raising Matters of Interest. Australia College of Health Service Executives; 2002. Available at http://www.achse.org.au/publications/ martins/drug.html [verified 8 December 2009].
6. Richardson JRJ, Segal L. Private health insurance and the Pharmaceutical Benefits Scheme: how effective has recent government policy been? Aust Health Rev 2004; 28(1): 34-49. doi:10.1071/AH040034
7. Harvey R. The effect of variations in patient contribution, income and doctor supply on the demand for PBS drugs. In: Tatchell PM, editor. Economics and health 1983 Proceedings of the fifth Australian conference of Health Economists. Technical Paper 8. Canberra: Health Economics Research Unit, Australian National University; 1984.
8. JohnstonM. The price elasticity of demand for pharmaceuticals. In: Selby Smith C, editor. Economics and Health 1990. Proceedings of the twelfth Australian Conference of Health Economists. Melbourne: Public Sector Management Institute, Monash University; 1991.
9. McManus P, Donnelly N, Henry DA, Hall W, Primrose J, Lindner J. Prescription drug utilisation following patient co-payment changes in Australia. Pharmacoepidemiol Drug Saf 1996; 5: 385-92. doi:10.1002/ (SICI)1099- 1557(199611)5:63.0.CO;2-8 (Pubitemid 27062320)
10. Sweeny K. The demand for PBS Medicine. Working Paper No. 45. Melbourne: Centre for Strategic Economic Studies, Victoria University of Technology; 2009. Available at http://www.cfses.com/documents/ wp45.pdf [verified 2 February 2011].
11. Lexchin J, Grootendorst P. Effects of prescription drug user fees on drug and health services use and on health status in vulnerable populations: a systematic review of the evidence. Int J Health Serv 2004; 34(1): 101-22. doi:10.2190/4M3E-L0YF-W1TD-EKG0 (Pubitemid 38393061)
12. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and health spending JAMA 2007; 298(1): 61-9. doi:10.1001/jama.298.1.61 (Pubitemid 47026771)
13. Hynd A, Roughead EE, Preen DB, Glover J, Bulsara M, Semmens J. The impact of co-payment increases on dispensings of government-subsidised medicines in Australia. Pharmacoepidemiol Drug Saf 2008; 17: 1091-9. doi:10.1002/pds.1670
14. Hynd A, Roughead EE, Preen DB, Glover J, Bulsara M, Semmens J. Increased patient co-payments and changes in PBS subsidised prescription medicines dispensed in Western Australia. Aust N Z J Public Health 2009; 33(3): 246-52. doi:10.1111/j.1753-6405.2009. 00383.x
15. Doran E, Robertson J, Rolfe I, Henry D. Patient co-payments and use of prescription medicines. Aust N Z J Public Health 2004; 28(1): 62-7. doi:10.1111/j.1467-842X.2004.tb00634.x (Pubitemid 38247836)
16. Blendon RJ, Schoen C, DesRoches CM, Osborn R, Scoles KL, Zapert K. Inequities in health care: a five-country survey. Health Aff 2002; 21(3): 182-91. doi:10.1377/hlthaff.21.3.182
17. Schoen C, Osborn R, Huynh PT, Doty M, Zapert K, Peugh J, Davis K. Taking the pulse of health care systems: experiences of patients with health problems in six countries. Health Aff 2005; 24: 509-25.
18. Davis K, Schoen C, Schoenbaum SC, DotyMM, Holmgren AL, Kriss JL Shea KK. Mirror, Mirror on the Wall: An International Update on the Comparative Performance of American Health Care. New York: Commonwealth Fund; 2007. Available at http://www.commonwealthfund. org/Content/Publications/Fund-Reports/ 2007/May/Mirror-Mirror-onthe- Wall-An-International-Update-on-the-Comparative- Performanceof- American-Healt.aspx [verified 2 February 2011].
19. Doran E, Robertson J, Henry D. Moral hazard and prescription medicine use. Soc Sci Med 2005; 60(7): 1437-43. doi:10.1016/j.socscimed.2004. 08.005
20. McAuley I. Behavioural economics and public policy: some insights. Working Paper. University of Canberra; 2007. Available at http://www. home.netspeed.com.au/mcau/academic/bepubpol.pdf [verified 2 February 2011].
21. Doran E. Pharmaceutical Affordability and Quality Use of Medicines. Australian Digital Theses Program Record No. 20264. Newcastle, NSW, University of Newcastle; 2003.
22. Wellbeing Watch. Newcastle: Hunter Valley Research Foundation; 2008. Available at http://www.hvrf.com.au/images/HVRF-Publications/wellbeing- watch-2008.pdf [verified 2 February 2011].
23. Walker A. Distributional impact of higher patient contributions to Australia's Pharmaceutical Benefits Scheme. Aust Health Rev 2000; 23(2): 32-46. doi:10.1071/AH000032
24. Reichmann G, Sommersguter-Riechmann M. Co-payments in the Austrian social health insurance system: analysing patient behaviour and patients views on the effects of co-payments. Health Policy 2004; 67: 75-91. doi:10.1016/S0168- 8510(03)00081-2 (Pubitemid 38058760)
25. Doran E, Robertson J. Australia's pharmaceutical cost sharing policy: reducing waste or affordability? Aust Health Rev 2009; 33(2): 231-40. doi:10.1071/AH090231